NICE has issued three major recommendations expanding access to Columvi-GemOx for DLBCL, talquetamab for relapsed myeloma, and delgocitinib for chronic hand eczema.
Doctors providing check-ups with a sign announcing free annual health checks and expanded insurance. Vietnam Sets Ambitious 2026 Plan for Free Annual Health Checks, Expanded Coverage, and System-Wide Reform Vietnam is preparing to deliver one of its most far-reaching public-health reforms in decades, a nationwide guarantee of one free annual health check or screening for … Read more
Biogen has earned a positive CHMP opinion for its high-dose nusinersen regimen, supported by strong DEVOTE study results showing major motor improvements and reduced mortality risk in SMA patients.
Novo Nordisk has introduced a $199 introductory price for Wegovy and Ozempic starter doses, alongside a permanent drop in monthly self-pay costs to $349.
J&J is acquiring Halda Therapeutics for $3.05B, gaining a precision prostate cancer therapy and a breakthrough induced-proximity platform.
The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability … Read more
CHMP’s November 2025 meeting delivered 10 new drug approvals, four indication extensions, and several high-profile withdrawals, highlighting continued momentum in gene therapy, oncology, immunology, and diagnostics.
The UK and ABPI have agreed to a third extension of the VPAG withdrawal deadline, moving it to December 16, 2025.
A stylized U.S. – Swiss handshake over rising economic indicators reflects the sweeping new trade deal tariffs slashed to 15% and Switzerland pledging $200B in U.S. investment through 2028. (Editorial Illustration) The United States and Switzerland have announced a major framework trade agreement that will see Washington slash tariffs on Swiss imports from 39% to … Read more
ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.